My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 175

    1.

    Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited.

    Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group.

    Diabetes. 2008 Apr;57(4):995-1001. Epub 2008 Jan 25.PMID: 18223010 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

    [No authors listed]

    Diabetes. 1995 Aug;44(8):968-83.PMID: 7622004 [PubMed - indexed for MEDLINE]Related articles

    3.

    The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.

    [No authors listed]

    Diabetes. 1996 Oct;45(10):1289-98.PMID: 8826962 [PubMed - indexed for MEDLINE]Related articles

    4.

    Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

    White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM.

    Arch Ophthalmol. 2008 Dec;126(12):1707-15.PMID: 19064853 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

    [No authors listed]

    N Engl J Med. 2000 Feb 10;342(6):381-9. Erratum in: N Engl J Med 2000 May 4;342(18):1376. PMID: 10666428 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.

    [No authors listed]

    Ophthalmology. 1995 Apr;102(4):647-61.PMID: 7724182 [PubMed - indexed for MEDLINE]Related articles

    7.

    The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial.

    [No authors listed]

    Arch Ophthalmol. 1995 Jan;113(1):36-51.PMID: 7826293 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

    Diabetes Control and Complications Trial Research Group.

    Diabetes Care. 2000 Aug;23(8):1084-91.PMID: 10937502 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.

    [No authors listed]

    Arch Ophthalmol. 1998 Jul;116(7):874-86. Erratum in: Arch Ophthalmol 1998 Nov;116(11):1469. PMID: 9682700 [PubMed - indexed for MEDLINE]Related articles

    10.

    The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial.

    Lachin JM, Genuth S, Nathan DM, Rutledge BN.

    Diabetes. 2007 Jul;56(7):1913-21. Epub 2007 Mar 14.PMID: 17360979 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

    White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

    J Pediatr. 2001 Dec;139(6):804-12.PMID: 11743505 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

    JAMA. 2002 May 15;287(19):2563-9.PMID: 12020338 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.

    Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM.

    Circulation. 2005 May 17;111(19):2446-53. Epub 2005 May 2.PMID: 15867184 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2008 Nov;31(11):2198-202. Epub 2008 Jul 23.PMID: 18650371 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited.

    Orchard TJ, Forrest KY, Ellis D, Becker DJ.

    Arch Intern Med. 1997 Sep 8;157(16):1851-6.PMID: 9290544 [PubMed - indexed for MEDLINE]Related articles

    16.

    Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.

    Genuth S.

    Endocr Pract. 2006 Jan-Feb;12 Suppl 1:34-41. Review.PMID: 16627378 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).

    [No authors listed]

    Diabetologia. 1998 Apr;41(4):416-23.PMID: 9562345 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes.

    McCarter RJ, Hempe JM, Gomez R, Chalew SA.

    Diabetes Care. 2004 Jun;27(6):1259-64.PMID: 15161772 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Glucose control in type 1 diabetes: from conventional to intensive therapy.

    Zinman B.

    Clin Cornerstone. 1998;1(3):29-38. Review.PMID: 10682171 [PubMed - indexed for MEDLINE]Related articles

    20.

    Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

    Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S.

    Diabetes. 1999 Apr;48(4):870-80.PMID: 10102706 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity